Resources Repository
-
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Economics/Finance | North America | Global | Policy/Regulation | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
OrganizationWeb Portal 2024Society for Benefit-Cost Analysis
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and …
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and practice of benefit-cost analysis and support evidence-based policy decisions. It addresses policy areas including public health, transportation, criminal justice, education, energy, environmental quality, homeland security, and poverty. Members include scholars and practitioners from around the world, who work in government, academia, nonprofits and private industry. Its members represent numerous disciplines such as economics, law, engineering, public policy, decision science, and…
Benefit-Cost Analysis | Military/Defense | Economics/Finance | Global | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Costing Methods | Social Determinants | Environmental Health | Business/Industry | Climate/Environment | Energy/Engineering | Education/Labor | Food/Agriculture | Government/Law | Health/Medicine | Science/Technology | Critical Thinking/Analysis -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Benefit-Cost Analysis | Economics/Finance | Global | Policy/Regulation | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Global Governance | Government/Law | Health/Medicine | Science/Technology -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Evidence Synthesis | Benefit-Cost Analysis | Economics/Finance | Global | Policy/Regulation | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Injuries/Accidents | Environmental Health | Global Governance | Climate/Environment | Culture/Society | Health/Medicine -
OrganizationWeb Portal 2024Council of Economic Advisers
The Council of Economic Advisers is an agency within the Executive Office of the President …
The Council of Economic Advisers is an agency within the Executive Office of the President and is charged with offering the President objective economic advice on the formulation of both domestic and international economic policy. The Council bases its recommendations and analysis on economic research and empirical evidence, using the best data available to support the President in setting our nation's economic policy. Learn about recent news and reports.
Evidence Synthesis | Benefit-Cost Analysis | Economics/Finance | North America | Policy/Regulation | Risk Analysis | Cost-Effectiveness Analysis | Government/Law -
BookPublication 2013Making Hard Decisions with Decision Tools, 3rd Edition
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas …
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas of decision analysis, without an overly technical explanation of the mathematics used in decision analysis. This new version has been purposefully written to be more relevant to students in business and engineering compared to previous versions. This new version also incorporates and implements the powerful DecisionTools® software by Palisade Corporation. At the end of each chapter, topics are illustrated with step-by-step instructions…
Probability/Bayes | Military/Defense | North America | Global | Policy/Regulation | Preferences/Values | Test Performance | Value of Information | Microsimulation | Decision Analysis | Business/Industry | Energy/Engineering | Health/Medicine | Science/Technology | Europe -
BookPublication 2012Elgar Companion to Health Economics, 2nd Edition
This collection brings together more than 50 contributions from some of the most influential researchers in …
This collection brings together more than 50 contributions from some of the most influential researchers in health economics. It covers theoretical and empirical issues in health economics, with a range of material on equity and efficiency in health care systems, health technology assessment and issues of concern for developing countries. This revised second edition is expanded to include four new chapters, while all existing chapters have been extensively updated. The Elgar Companion to Health Economics, Second Edition…
Probability/Bayes | Decision Theory | Economics/Finance | Global | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Costing Methods | Value of Information | Cost-Effectiveness Analysis | Health Systems | Health/Medicine -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Benefit-Cost Analysis | Economics/Finance | North America | Policy/Regulation | Mathematical Models | State-Transition | Infectious Diseases | Business/Industry | Government/Law | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Economics/Finance | North America | Policy/Regulation | Value of Information | State-Transition | Infectious Diseases | Europe